DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA

被引：2
|
作者：
Elgart, J. F. [1 ]
Prestes, M. [1 ]
Gonzalez, L. [1 ]
Aschner, P. [2 ]
Garrido Lecca, S. [3 ]
Aiello, E. [4 ]
Jimenez, C. [5 ]
Gagliardino, J. J. [1 ]
机构：
[1] UNLP CONICET La Plata, Ctr Colaborador OPS OMS, CENEXA Ctr Endocrinol Expt & Aplicada, Buenos Aires, DF, Argentina
[2] Pontificia Univ Javeriana, Bogota, Colombia
[3] Bristol Myers Squibb Co, Lima, Peru
[4] Bristol Myers Squibb Co, Buenos Aires, DF, Argentina
[5] Bristol Myers Squibb Co, Bogota, Colombia
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1442
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：A247 / A247
页数：1
相关论文
共 50 条
  • [31] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Hu, Shanshan
    Deng, Xun
    Ma, Yanjiao
    Li, Zhilei
    Wang, Yuhang
    Wang, Yong
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (01) : 69 - 79
  • [32] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Shanshan Hu
    Xun Deng
    Yanjiao Ma
    Zhilei Li
    Yuhang Wang
    Yong Wang
    [J]. Applied Health Economics and Health Policy, 2021, 19 : 69 - 79
  • [33] Improvement in Glycemic Control and Reduction in Body Weight over 52 Weeks with Dapagliflozin as Add-on Therapy to Metformin plus Sulfonylurea
    Matthaei, Stephan
    Bowering, Keith
    Rohwedder, Katja
    Grohl, Anke
    Johnsson, Eva
    [J]. DIABETES, 2014, 63 : A70 - A71
  • [34] Cost-effectiveness of add-on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
    Abushanab, Dina
    Chbib, Salma
    Kaddoura, Rasha
    Al Hail, Moza
    Rouf, Palli Valappila Abdul
    El Kassem, Wessam
    Shah, Jassim
    Nair, Ramesh Kumar Ravindran
    Al-Badriyeh, Daoud
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 404 - 417
  • [35] ADD-ON THERAPY IN BREAST CANCER - PROBABILITY OF COST-EFFECTIVENESS IN ECONOMIC ANALYSES
    Przada-Machno, P.
    Marzec, M.
    Borowiack, E.
    Nowotarska, A.
    Jarosz, J.
    Szczuka, A.
    Konopka-Pliszka, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A445 - A445
  • [36] The cost-effectiveness of newer drugs as add-on therapy for children with focal epilepsies
    Frew, Emma J.
    Sandercock, Josie
    Whitehouse, William P.
    Bryan, Stirling
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2007, 16 (02): : 99 - 112
  • [37] ADD-ON MEMORIES - COST-EFFECTIVENESS AND BETTER PERFORMANCE
    不详
    [J]. DATA MANAGEMENT, 1979, 17 (02): : 22 - 23
  • [38] Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy
    Vera-Llonch, Montserrat
    Brandenburg, Nancy A.
    Oster, Gerry
    [J]. EPILEPSIA, 2008, 49 (03) : 431 - 437
  • [39] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [40] Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes
    Cai, Xiaoling
    Shi, Lizheng
    Yang, Wenjia
    Gu, Shuyan
    Chen, Yingyao
    Nie, Lin
    Ji, Linong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 336 - 343
12345